Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A haploid genetic screen identifies the G 1 /S regulatory machinery as a determinant of Wee1 inhibitor sensitivity

23 Nov 2015

Abstract excerpt

The Wee1 cell cycle checkpoint kinase prevents premature mitotic entry by inhibiting cyclin-dependent kinases. Chemical inhibitors of Wee1 are currently being tested clinically as targeted anticancer drugs. Wee1 inhibition is thought to be preferentially cytotoxic in p53-defective cancer cells. However, TP53 mutant cancers do not respond consistently to Wee1 inhibitor treatment, indicating the existence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26598692
DOI: 10.1073/pnas.1505283112

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A haploid genetic screen identifies the G 1 /S regulatory machinery as a determinant of Wee1 inhibitor sensitivityPMID 26598692Read ↗

Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase InhibitionSemantic proximity Read ↗

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.Semantic proximity Read ↗

The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations.Semantic proximity Read ↗

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 MutationsSemantic proximity Read ↗

Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 MutationsSemantic proximity Read ↗

Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging AgentsSemantic proximity Read ↗

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsSemantic proximity Read ↗

<i>TP53</i> loss initiates chromosomal instability in high-grade serous ovarian cancerSemantic proximity Read ↗

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in CancerSemantic proximity Read ↗

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775Semantic proximity Read ↗

Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.Semantic proximity Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.